Evidence map›Paper›PMID 34510812›Full record

ReviewAndrology2022

Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.

Alexander W Pastuszak, Marc Gittelman, James P Tursi, Jonathan S Jaffe, David Schofield, Martin M Miner

Open access · hybridAbstract readReview
In one paragraph

Review in Andrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. A Current Perspective on Delayed Puberty and Its ManagementJournal of clinical research in pediatric endocrinology · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Alexander W PastuszakUniversity of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID 0000-0002-6740-8348
Marc Gittelman21st Century Oncology, Uro-Medix/GenesisCare, Aventura, Florida, USA.
James P TursiAntares Pharma, Inc., Ewing, New Jersey, USA.
Jonathan S JaffeAntares Pharma, Inc., Ewing, New Jersey, USA.
David SchofieldAntares Pharma, Inc., Ewing, New Jersey, USA.
Martin M MinerMen's Health Center, Miriam Hospital, Providence, Rhode Island, USA.
Antares Pharma (United States) · US21st Century Oncology (United States) · USMiriam Hospital · USUniversity of Utah · US

Funding

Antares Pharma, Inc. (Ewing, NJ)
6 · The paper itself

Abstract

backgroundTo improve symptoms associated with testosterone deficiency, many testosterone therapies are available that aim to restore serum testosterone (T) levels to the normal physiologic range. The magnitude, frequency, and duration between peak and trough T concentrations vary with route of administration, and none reflect normal endogenous daily diurnal T variations.

objectiveTo compare pharmacokinetic profiles of serum T from approved T formulations with endogenous diurnal T variations in young and older men, and to consider whether there may be value in mimicking the diurnal T rhythmicity with exogenous testosterone therapies as men age. MATERIALS AND

methodsA literature search of studies examining the diurnal variation of endogenous T in healthy men and men with testosterone deficiency was performed using PubMed in January 2020. Additional searches for serum T pharmacokinetic profiles of various testosterone therapy formulations were also conducted. Prescribing information for various T formulations was also reviewed. DISCUSSION AND

conclusionEndogenous diurnal T variation is well described and appears to be blunted naturally as men age. Men with testosterone deficiency lack diurnal T variation and exhibit a flatter T profile compared with eugonadal men. Some T replacement options provide intraday T level variations similar to normal circadian secretion, and others provide a flatter exposure profile reflective of depot release. Others provide profiles that exceed the frequency and physiologic range of the natural diurnal variation of T. All exogenous T replacement dosing targets an increase in average T levels to within the normal physiologic range and improves symptoms associated with low T, but no single testosterone therapy can exactly mimic the normal diurnal T patterns seen in younger men and the blunted circadian T secretion of older men.

Indexed as

Age FactorsAgingCircadian RhythmHormone Replacement TherapyHumansHypogonadismMaleTestosteroneTestosterone CongenersTestosteroneTestosterone Congenersdiurnal variationtestosterone deficiencytestosterone therapy

Identifiers

PMID34510812
PMCPMC9293229
OpenAlexW3199434919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.